

Stephen J Clarke

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/391072/stephen-j-clarke-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

278
papers

15,088
citations

56
h-index

118
g-index

288
ext. papers

17,577
ext. citations

4.6
avg. IF

6.37
L-index

#	Paper	IF	Citations
278	Exploring the role of extracellular vesicles and their protein cargo in lung cancer metastasis: a review.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 171, 103603	7	0
277	Liver Isolation Oxaliplatin (LIOX): Long Term Survival from a New Locoregional Technique for Chemorefractory Patients with Colorectal Liver Metastases.. <i>Annals of Surgical Oncology</i> , 2022 , 1	3.1	0
276	Effect of Cancer Pain Guideline Implementation on Pain Outcomes Among Adult Outpatients With Cancer-Related Pain: A Stepped Wedge Cluster Randomized Trial.. <i>JAMA Network Open</i> , 2022 , 5, e220060	10.4	0
275	Life-threatening diarrhea in neuroendocrine tumors: two case reports. <i>Journal of Medical Case Reports</i> , 2021 , 15, 542	1.2	1
274	A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach. <i>American Journal of Surgical Pathology</i> , 2021 , 45, 394-404	6.7	4
273	Increased rates of cetuximab reactions in tick prevalent regions and a proposed protocol for risk mitigation. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021 , 17, 448-453	1.9	4
272	Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib. <i>Translational Lung Cancer Research</i> , 2021 , 10, 1623-1634	4.4	1
271	Emerging biological therapies for the treatment of malignant pleural mesothelioma. <i>Expert Opinion on Emerging Drugs</i> , 2021 , 26, 179-192	3.7	2
270	Computed tomography (CT)-defined sarcopenia and myosteatosis are prevalent in patients with neuroendocrine neoplasms (NENs) treated with peptide receptor radionuclide therapy (PRRT). <i>European Journal of Clinical Nutrition</i> , 2021 ,	5.2	3
269	Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab □ durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9047-9047	2.2	3
268	EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021 , 22, e859-e869	4.9	6
267	Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2021 , 155, 28-33	5.9	5
266	The Gut Microbiome and Gastrointestinal Toxicities in Pelvic Radiation Therapy: A Clinical Review. <i>Cancers</i> , 2021 , 13,	6.6	3
265	Marked improvement in hyperammonaemic encephalopathy from multimodal treatment of metastatic neuroendocrine tumour. <i>BMJ Case Reports</i> , 2021 , 14,	0.9	
264	Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. <i>Medical Journal of Australia</i> , 2021 , 214, 475-483	4	12
263	The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?. <i>Cancers</i> , 2021 , 13,	6.6	7
262	Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. <i>Lung Cancer</i> , 2021 , 159, 66-73	5.9	2

261	Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review. <i>Frontiers in Oncology</i> , 2021 , 11, 706331	5.3	5
260	Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 2543-2550	3.6	2
259	Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211019675	5.4	1
258	Red blood cells exposed to cancer cells in culture have altered cytokine profiles and immune function. <i>Scientific Reports</i> , 2020 , 10, 7727	4.9	5
257	ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling. <i>Oncologist</i> , 2020 , 25, 641-649	5.7	4
256	Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells. <i>Cancer Cell</i> , 2020 , 37, 354-370.e7	24.3	14
255	Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 2020 , 10, 237	5.3	11
254	The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]. <i>PLoS ONE</i> , 2020 , 15, e0229900	3.7	9
253	Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2020 , 49, 224-229	2.6	3
252	Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model. <i>PLoS ONE</i> , 2020 , 15, e0226444	3.7	11
251	The Effects of Tai Chi and Qigong on Immune Responses: A Systematic Review and Meta-Analysis. <i>Medicines (Basel, Switzerland)</i> , 2020 , 7,	4.1	6
250	Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 1013-1026	6.2	2
249	A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. <i>Lung Cancer</i> , 2020 , 142, 34-40	5.9	16
248	Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 150, 102949	7	11
247	Serum bicarbonate is a marker of peri-operative mortality but is not associated with long term survival in colorectal cancer. <i>PLoS ONE</i> , 2020 , 15, e0228466	3.7	2
246	Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100075	1.4	1
245	The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy. <i>Acta Oncologica</i> , 2020 , 59, 20-27	3.2	3
244	High Metabolic Tumour Volume on 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Poor Survival from Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2020 , 110, 950-958	5.6	8

243	Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patients. <i>Supportive Care in Cancer</i> , 2020 , 28, 3399-3407	3.9	6
242	Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. <i>Annals of Oncology</i> , 2020 , 31, 1553-1560	10.3	21
241	The Effects of Acupuncture on Cancer-Related Fatigue: Updated Systematic Review and Meta-Analysis. <i>Integrative Cancer Therapies</i> , 2020 , 19, 1534735420949679	3	8
240	Science and art of anticancer drug dosing: nine steps to personalised therapy. <i>Internal Medicine Journal</i> , 2020 , 50, 992-996	1.6	
239	Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay. <i>Nanotheranostics</i> , 2020 , 4, 224-232	5.6	15
238	Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019 , 63, 272-280	1.7	5
237	Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. <i>European Journal of Cancer</i> , 2019 , 109, 28-35	7.5	50
236	Treatment and management of adrenal cancer in a specialized Australian endocrine surgical unit: approaches, outcomes and lessons learnt. <i>ANZ Journal of Surgery</i> , 2019 , 89, 48-52	1	4
235	Straddling medical specialties: should we have more comprehensive advanced training?. <i>Internal Medicine Journal</i> , 2019 , 49, 669-671	1.6	1
234	Tumor sidedness is not an independent prognostic marker of colorectal cancer patients undergoing curative resection: A retrospective cohort study. <i>PLoS ONE</i> , 2019 , 14, e0218207	3.7	6
233	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 782-794	9.7	113
232	Mouse Model of Mutated in Colorectal Cancer Gene Deletion Reveals Novel Pathways in Inflammation and Cancer. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019 , 7, 819-839	7.9	4
231	High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes. <i>Lung Cancer</i> , 2019 , 130, 35-41	5.9	15
230	Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 1504	5.3	3
229	Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation. <i>British Journal of Pharmacology</i> , 2019 , 176, 3712-3722	8.6	6
228	Mass Cytometry Reveals a Sustained Reduction in CD16 Natural Killer Cells Following Chemotherapy in Colorectal Cancer Patients. <i>Frontiers in Immunology</i> , 2019 , 10, 2584	8.4	8
227	The vermiform appendix: an immunological organ sustaining a microbiome inoculum. <i>Clinical Science</i> , 2019 , 133, 1-8	6.5	19
226	Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study. <i>European Journal of Surgical Oncology</i> , 2019 , 45, 218-224	3.6	16

225	A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 575-583	9.7	60
224	Challenges in chemotherapy delivery: comparison of standard chemotherapy delivery to locoregional vascular mass fluid transfer. <i>Future Oncology</i> , 2018 , 14, 647-663	3.6	13
223	Pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALK+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018 , 14, e275-e282	1.9	4
222	Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 638-648	9.7	63
221	Neutrophil to lymphocyte ratio and early clinical outcomes in patients with acute ischemic stroke. <i>Journal of the Neurological Sciences</i> , 2018 , 387, 115-118	3.2	50
220	Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer. <i>ESMO Open</i> , 2018 , 3, e000302	6	3
219	A Longitudinal Investigation of Inflammatory Markers in Colorectal Cancer Patients Perioperatively Demonstrates Benefit in Serial Remeasurement. <i>Annals of Surgery</i> , 2018 , 267, 1119-1125	7.8	18
218	Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. <i>Gut</i> , 2018 , 67, 2142-2155	19.2	71
217	Complete response in a patient with stage IV adrenocortical carcinoma treated with adjuvant trans-catheter arterial chemo-embolization (TACE). <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018 , 14, 279-281	1.9	8
216	The role of proteomics in the age of immunotherapies. <i>Mammalian Genome</i> , 2018 , 29, 757-769	3.2	7
215	Accreditation Standard Guideline Initiative for Tai Chi and Qigong Instructors and Training Institutions. <i>Medicines (Basel, Switzerland)</i> , 2018 , 5,	4.1	4
214	A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis. <i>Npj Systems Biology and Applications</i> , 2018 , 4, 20	5	33
213	Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e617-e629	3.8	31
212	Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4123-4123	2.2	38
211	Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018 , 14, 256-263	1.9	7
210	Acupuncture in Oncology: The Effectiveness of Acupuncture May Not Depend on Needle Retention Duration. <i>Integrative Cancer Therapies</i> , 2018 , 17, 458-466	3	8
209	Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2532-2537	2.2	217
208	The role of adjuvant probiotics to attenuate intestinal inflammatory responses due to cancer treatments. <i>Beneficial Microbes</i> , 2018 , 9, 899-916	4.9	9

207	A randomised controlled trial of an advance care planning intervention for patients with incurable cancer. <i>British Journal of Cancer</i> , 2018 , 119, 1182-1190	8.7	30
206	The integration of pharmacology and pathophysiology into locoregional chemotherapy delivery via mass fluid transfer. <i>Journal of Controlled Release</i> , 2018 , 292, 18-28	11.7	1
205	Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV). <i>BMJ Open</i> , 2018 , 8, e020745	3	13
204	The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal Cancer. <i>Annals of Surgery</i> , 2017 , 265, 539-546	7.8	165
203	Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2017 , 104, 209-222	5.6	9
202	Factors affecting whether or not cancer patients consider using acupuncture. <i>Acupuncture in Medicine</i> , 2017 , 35, 107-113	1.9	8
201	Impact of physical activity on fatigue and quality of life in people with advanced lung cancer: a randomized controlled trial. <i>Annals of Oncology</i> , 2017 , 28, 1889-1897	10.3	53
200	Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis. <i>EJNMMI Research</i> , 2017 , 7, 46	3.6	34
199	Prognostic and predictive biomarkers in neuroendocrine tumours. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 113, 268-282	7	33
198	Osimertinib induced bullous dermatitis. <i>Cancer Treatment and Research Communications</i> , 2017 , 13, 25-262		0
197	Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance. <i>Theranostics</i> , 2017 , 7, 1149-1158	12.1	115
196	Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. <i>Lancet Oncology, The</i> , 2017 , 18, 1386-1396	21.7	330
195	Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017 , 13, 296-303	1.9	12
194	Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 599-610	6.1	47
193	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology, The</i> , 2017 , 18, 1159-1171	21.7	193
192	Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre. <i>European Journal of Surgical Oncology</i> , 2017 , 43, 1711-1717	3.6	22
191	Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target. <i>Histopathology</i> , 2017 , 70, 402-411	7.3	38
190	Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. <i>International Journal of Cancer</i> , 2017 , 140, 431-439	7.5	3

189	Changing Therapeutic Paradigms: Predicting mCRC Lesion Response to Selective Internal Radionuclide Therapy (SIRT) based on Critical Absorbed Dose Thresholds: A Case Study. <i>Asia Oceania Journal of Nuclear Medicine and Biology</i> , 2017 , 5, 66-69	0.7	2
188	PET monitoring of liver directed selective internal radionuclide therapy for metastatic gastro-oesophageal cancer. <i>BMJ Case Reports</i> , 2016 , 2016,	0.9	
187	The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. <i>Lung Cancer</i> , 2016 , 102, 21-27	5.9	10
186	Advance care planning in patients with incurable cancer: study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2016 , 6, e012387	3	14
185	Safety and Feasibility of Repeatable Hepatic Vascular Isolation Chemotherapy: A Pilot Study. <i>Annals of Surgical Oncology</i> , 2016 , 23, 3699-3708	3.1	3
184	Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and non-oropharyngeal patients. <i>BMC Cancer</i> , 2016 , 16, 124	4.8	45
183	A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2016 , 114, 524-31	8.7	15
182	Symptom Clusters in Advanced Cancer Patients: An Empirical Comparison of Statistical Methods and the Impact on Quality of Life. <i>Journal of Pain and Symptom Management</i> , 2016 , 51, 88-98	4.8	53
181	The lymphocyte-to-monocyte ratio as a predictor of overall survival in comparison to established systemic markers of inflammation in resectable colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 593-593	2.2	1
180	Adjuvant therapy in pancreatic adenocarcinoma: A systemic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 330-330	2.2	
179	Change in inflammatory status as a prognostic marker of overall survival in colorectal patients undergoing resection.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6571-6571	2.2	
178	Primary Pericardial Sarcoma with Right Atrial Invasion and Multiple Bilateral Pulmonary Metastases in a Patient with Hereditary Nonpolyposis Colorectal Cancer. <i>Case Reports in Oncological Medicine</i> , 2016 , 2016, 6208029	0.9	
177	Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET). <i>PLoS ONE</i> , 2016 , 11, e0158140	3.7	14
176	Oxidative stress in prostate cancer patients: A systematic review of case control studies. <i>Prostate International</i> , 2016 , 4, 71-87	3.4	49
175	Analytical performance of nano-LC-SRM using nondepleted human plasma over an 18-month period. <i>Proteomics</i> , 2016 , 16, 2118-27	4.8	6
174	Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. <i>Epigenomics</i> , 2016 , 8, 1079-85	4.4	124
173	Inflammatory Markers Have a Role in Renal Cell Carcinoma Prognosis. <i>European Urology Focus</i> , 2016 , 2, 341-342	5.1	2
172	Eastern Cooperative Oncology Group score: Agreement between non-small-cell lung cancer patients and their oncologists and clinical implications. <i>Cancer Treatment Communications</i> , 2016 , 5, 17-21		11

171	Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study. <i>Annals of Oncology</i> , 2016 , 27, 1761-7	10.3	37
170	Exhaled breath condensate for lung cancer protein analysis: a review of methods and biomarkers. <i>Journal of Breath Research</i> , 2016 , 10, 034001	3.1	25
169	Dramatic response to selective internal radiation therapy for unresectable hepatocellular carcinoma. <i>Oxford Medical Case Reports</i> , 2015 , 2015, 194-5	0.6	
168	Localized malignant pleural mesothelioma with renal metastasis. <i>Oxford Medical Case Reports</i> , 2015 , 2015, 170-2	0.6	7
167	A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, 1467-9	10.2	54
166	Reporting in studies of protein biomarkers of prognosis in colorectal cancer in relation to the REMARK guidelines. <i>Proteomics - Clinical Applications</i> , 2015 , 9, 1078-86	3.1	6
165	Immunohistochemical validation of overexpressed genes identified by global expression microarrays in adrenocortical carcinoma reveals potential predictive and prognostic biomarkers. <i>Oncologist</i> , 2015 , 20, 247-56	5.7	16
164	Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4085-92	2.2	122
163	Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: an evidence-based benchmark for cancer care. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015 , 11, 85-92	1.9	4
162	Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015 , 11, 4-14	1.9	12
161	PHYTOTHERAPIES 2015 , 536-553		
160	Neutrophil-to-lymphocyte ratio in head and neck cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2015 , 59, 514-519	1.7	36
159	Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors. <i>Medicine (United States)</i> , 2015 , 94, e1281	1.8	41
158	Adjuvant Iodine (131) Lipiodol after Resection of Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2015 , 2015, 746917	4.5	5
157	MicroRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma. <i>Oncotarget</i> , 2015 , 6, 36675-88	3.3	62
156	Pathogenic PALB2 mutation in metastatic pancreatic adenocarcinoma and neuroendocrine tumour: A case report. <i>Molecular and Clinical Oncology</i> , 2015 , 3, 817-819	1.6	9
155	Surface profiles of live colorectal cancer cells and tumor infiltrating lymphocytes from surgical samples correspond to prognostic categories. <i>Journal of Immunological Methods</i> , 2015 , 416, 59-68	2.5	6
154	Improving Outcomes in Adrenocortical Cancer: An Australian Perspective. <i>Annals of Surgical Oncology</i> , 2015 , 22, 2309-16	3.1	19

153	The relationship between nutritional status, inflammatory markers and survival in patients with advanced cancer: a prospective cohort study. <i>Supportive Care in Cancer</i> , 2015 , 23, 385-91	3.9	60
152	Preliminary direct evidence of a dose-response relationship for [Y-90]-microsphere selective internal radionuclide therapy (SIRT) in hepatic malignancy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 11064-11064 ¹		
151	The impact of physical activity on fatigue and quality of life in lung cancer patients: A randomised controlled trial (RCT).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9507-9507	2.2	1
150	Biomarkers in Metastatic Colorectal Cancer. <i>Biomarkers in Disease</i> , 2015 , 601-629		
149	Nomograms for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 659-659 ²		
148	Neutrophil/lymphocyte ratio (NLR) and FDG PET as predictive measures of response and prognosis in patients treated with Y-90 microsphere selective internal radionuclide therapy (SIRT).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e22137-e22137	2.2	
147	Calculators for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3555-3555 ²		
146	Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. <i>Scientific Reports</i> , 2014 , 4, 6152	4.9	13
145	Adverse tumor biology associated with mesenterico-portal vein resection influences survival in patients with pancreatic ductal adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2014 , 21, 1937-47	3.1	32
144	Comprehensive glycomics comparison between colon cancer cell cultures and tumours: implications for biomarker studies. <i>Journal of Proteomics</i> , 2014 , 108, 146-62	3.9	47
143	KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer. <i>International Journal of Cancer</i> , 2014 , 134, 2820-8	7.5	39
142	Cancer-related inflammation and treatment effectiveness. <i>Lancet Oncology, The</i> , 2014 , 15, e493-503	21.7	945
141	Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 317-24	3.3	53
140	Malignant Cardiac Tamponade from Non-Small Cell Lung Cancer: Case Series from the Era of Molecular Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2014 , 4, 75-84	5.1	9
139	Diagnosis of gastrointestinal bleeding: A practical guide for clinicians. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2014 , 5, 467-78	3.2	103
138	Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines. <i>Cancer Immunology Research</i> , 2014 , 2, 469-79	12.5	18
137	Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. <i>BMC Cancer</i> , 2014 , 14, 897	4.8	41
136	Comment on Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma. <i>British Journal of Cancer</i> , 2014 , 111, 2376	8.7	3

135	Cognitive function and fatigue after diagnosis of colorectal cancer. <i>Annals of Oncology</i> , 2014 , 25, 2404-2412	7.6	76
134	Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. <i>British Journal of Cancer</i> , 2014 , 111, 1860-9	8.7	52
133	Enduring complete metabolic response in metastatic adenocarcinoma of the gastro-oesophageal junction. <i>Oxford Medical Case Reports</i> , 2014 , 2014, 105-6	0.6	
132	From mice to men: GEMMs as trial patients for new NSCLC therapies. <i>Seminars in Cell and Developmental Biology</i> , 2014 , 27, 118-27	7.5	16
131	Effects of qigong on quality of life, fatigue, stress, neuropathy, and sexual function in women with metastatic breast cancer: A feasibility study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e20712-e20712	2.2	1
130	Depletion of white adipose tissue in cancer cachexia syndrome is associated with inflammatory signaling and disrupted circadian regulation. <i>PLoS ONE</i> , 2014 , 9, e92966	3.7	54
129	Prognostic significance of circulating secreted protein acidic and rich in cysteine (SPARC) in malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7580-7580	2.2	
128	Old and new prognostic factors in a series of 910 patients with malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7586-7586	2.2	
127	Prognostic utility of the preoperative neutrophil/lymphocyte ratio combined with BRAF and MMR status in colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e14529-e14529	2.2	
126	Extra-hepatic cancer represses hepatic drug metabolism via interleukin (IL)-6 signalling. <i>Pharmaceutical Research</i> , 2013 , 30, 2270-8	4.5	14
125	An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic Colorectal Cancer Treated with bevacizumab (Avastin®)[ASCENT]. <i>BMC Cancer</i> , 2013 , 13, 120	4.8	16
124	Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma. <i>Supportive Care in Cancer</i> , 2013 , 21, 1879-84	3.9	8
123	CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. <i>Pharmacogenomics</i> , 2013 , 14, 137-49	2.6	40
122	Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. <i>SpringerPlus</i> , 2013 , 2, 126		13
121	The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 88, 218-30	7	827
120	Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 85, 121-35	7	17
119	Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 423-30	3.3	29
118	Preoperative neutrophil/lymphocyte ratio predicts overall survival but does not predict recurrence or cancer-specific survival after curative resection of node-positive colorectal cancer. <i>BMC Cancer</i> , 2013 , 13, 442	4.8	35

117	A randomized controlled pilot trial comparing the impact of access to clinical endocrinology video demonstrations with access to usual revision resources on medical student performance of clinical endocrinology skills. <i>BMC Medical Education</i> , 2013 , 13, 135	3.3	27
116	Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia. <i>Internal Medicine Journal</i> , 2013 , 43, 402-10	1.6	15
115	Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. <i>Supportive Care in Cancer</i> , 2013 , 21, 697-705	3.9	33
114	Vitamin supplementation in patients receiving pemetrexed for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2013 , 82, 511	5.9	1
113	Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma. <i>Clinical Lung Cancer</i> , 2013 , 14, 164-71	4.9	8
112	Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. <i>Clinical Lung Cancer</i> , 2013 , 14, 70-7	4.9	48
111	BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. <i>American Journal of Surgical Pathology</i> , 2013 , 37, 1592-602	6.7	112
110	Randomized controlled trial of a structured intervention to facilitate end-of-life decision making in patients with advanced cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3403-10	2.2	65
109	Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: trends in Australia and a literature review. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013 , 9, 273-9	1.9	6
108	Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 148-55	1.9	29
107	Diagnostic Accuracy of Imaging Modalities in the Evaluation of Vascular Invasion in Pancreatic Adenocarcinoma: A Meta-Analysis. <i>World Journal of Oncology</i> , 2013 , 4, 74-82	16.7	4
106	Use of inflammatory markers to triage cancer patients requiring nutritional assessment and interventions.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e17541-e17541	2.2	
105	Use of adjuvant chemotherapy in stage C (III) rectal cancer: comparison of data from matched patients in a teaching hospital@ clinico-pathological database. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012 , 8, 346-55	1.9	1
104	Reporting clinical trial information: colorectal cancer trials at Sydney Cancer Centre. <i>Internal Medicine Journal</i> , 2012 , 42, 416-21	1.6	
103	Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 125-35	3.5	15
102	Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. <i>Lancet Oncology, The</i> , 2012 , 13, 1225-33	21.7	389
101	The ticking time-bomb of asbestos: its insidious role in the development of malignant mesothelioma. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 84, 200-12	7	42
100	Remarkable temporal stability of high-abundance human plasma proteins assessed by targeted mass spectrometry. <i>Proteomics - Clinical Applications</i> , 2012 , 6, 626-34	3.1	6

99	Body image as a predictor of psychopathology in surgical patients with colorectal disease. <i>Journal of Psychosomatic Research</i> , 2012 , 73, 459-63	4.1	44
98	Overexpression of protein S100A4 is independently associated with overall survival in stage C colonic cancer but only in cytoplasm at the advancing tumour front. <i>International Journal of Colorectal Disease</i> , 2012 , 27, 1409-17	3	7
97	Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review. <i>Oncologist</i> , 2012 , 17, 1475-81	5.7	189
96	Glutathione S-transferase Pi expression predicts response to adjuvant chemotherapy for stage C colon cancer: a matched historical control study. <i>BMC Cancer</i> , 2012 , 12, 196	4.8	10
95	The impact of physical activity on fatigue and quality of life in lung cancer patients: a randomised controlled trial protocol. <i>BMC Cancer</i> , 2012 , 12, 572	4.8	22
94	Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 203-24	6.2	60
93	The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. <i>Lung Cancer</i> , 2012 , 75, 248-54	5.9	28
92	A critical review of the effects of medical Qigong on quality of life, immune function, and survival in cancer patients. <i>Integrative Cancer Therapies</i> , 2012 , 11, 101-10	3	39
91	Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2012 , 20, 1235-42	3.9	152
90	Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. <i>Supportive Care in Cancer</i> , 2012 , 20, 1869-74	3.9	31
89	A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. <i>British Journal of Cancer</i> , 2012 , 107, 695-9	8.7	290
88	Src tyrosine kinase phosphorylation of nuclear receptor HNF4 α correlates with isoform-specific loss of HNF4 α in human colon cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 2302-7	11.5	55
87	The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials. <i>Annals of Oncology</i> , 2012 , 23, 1229-1233	10.3	13
86	Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice. <i>Cancer Research</i> , 2012 , 72, 4372-82	10.1	100
85	A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer. <i>Oncology Reports</i> , 2012 , 28, 763-7	3.5	3
84	Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4644-4644	2.2	1
83	Cognitive function and fatigue in colorectal cancer (CRC) patients: A prospective longitudinal controlled study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 9021-9021	2.2	2
82	Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. <i>Aging</i> , 2012 , 4, 133-43	5.6	58

81	Inflammation in malignant mesothelioma - friend or foe?. <i>Annals of Cardiothoracic Surgery</i> , 2012 , 1, 516-227		21
80	Pathophysiology of Bone Metastases 2012 , 59-84		
79	Use of inflammatory markers to guide cancer treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 90, 475-8	6.1	55
78	Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]. <i>European Journal of Cancer</i> , 2011 , 47, 1826-36	7.5	11
77	The relationship between body image disturbance and distress in colorectal cancer patients with and without stomas. <i>Journal of Psychosomatic Research</i> , 2011 , 70, 395-402	4.1	77
76	Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 602-5	8.9	47
75	Validation of tissue microarray technology in malignant pleural mesothelioma. <i>Pathology</i> , 2011 , 43, 128-33	3.5	24
74	Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1923-9	8.9	71
73	Colorectal cancer cell surface protein profiling using an antibody microarray and fluorescence multiplexing. <i>Journal of Visualized Experiments</i> , 2011 ,	1.6	9
72	Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. <i>Pathology</i> , 2011 , 43, 313-7	1.6	14
71	Clinicopathological correlates and prognostic significance of glutathione S-transferase Pi expression in 468 patients after potentially curative resection of node-positive colonic cancer. <i>Histopathology</i> , 2011 , 59, 1057-70	7.3	10
70	Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011 , 7, 376-84	1.9	1
69	Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. <i>British Journal of Cancer</i> , 2011 , 104, 1288-95	8.7	334
68	Using the Distress Thermometer and Hospital Anxiety and Depression Scale to screen for psychosocial morbidity in patients diagnosed with colorectal cancer. <i>Journal of Affective Disorders</i> , 2011 , 131, 412-6	6.6	32
67	Proteomic comparison of colorectal tumours and non-neoplastic mucosa from paired patient samples using iTRAQ mass spectrometry. <i>Molecular BioSystems</i> , 2011 , 7, 2997-3005		28
66	Patient and oncologist estimates of survival in advanced cancer patients. <i>Psycho-Oncology</i> , 2011 , 20, 213-8	3.9	18
65	XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. <i>British Journal of Cancer</i> , 2011 , 105, 58-64	8.7	160
64	Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 79, 224-50	7	30

63	Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2077-84	2.2	81
62	Liver membrane proteome glycosylation changes in mice bearing an extra-hepatic tumor. <i>Molecular and Cellular Proteomics</i> , 2011 , 10, M900538MCP200	7.6	34
61	Extrahepatic cancer suppresses nuclear receptor-regulated drug metabolism. <i>Clinical Cancer Research</i> , 2011 , 17, 3170-80	12.9	27
60	An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 1395-410	5.5	15
59	Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. <i>Clinical Cancer Research</i> , 2011 , 17, 3019-28	12.9	90
58	Clinical pharmacology of chemotherapy agents in older people with cancer. <i>Current Gerontology and Geriatrics Research</i> , 2011 , 2011, 628670	2.9	11
57	Successes, challenges and future directions 2011 , 84-95		
56	The use and perceived benefits resulting from the use of complementary and alternative medicine by cancer patients in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010 , 6, 342-9	1.9	58
55	Clinicopathological correlates and prognostic significance of maspin expression in 450 patients after potentially curative resection of node-positive colonic cancer. <i>Histopathology</i> , 2010 , 56, 319-30	7.3	16
54	Inflammation and cancer: causes and consequences. <i>Clinical Pharmacology and Therapeutics</i> , 2010 , 87, 504-8	6.1	149
53	Malignant mesothelioma. <i>Internal Medicine Journal</i> , 2010 , 40, 742-50	1.6	25
52	Fascin expression predicts survival after potentially curative resection of node-positive colon cancer. <i>American Journal of Surgical Pathology</i> , 2010 , 34, 656-66	6.7	31
51	High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. <i>Clinical Cancer Research</i> , 2010 , 16, 5805-13	12.9	238
50	Clinical trial information as a measure of quality cancer care. <i>Journal of Oncology Practice</i> , 2010 , 6, 170-13,1	3.1	5
49	Impact of medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial. <i>Annals of Oncology</i> , 2010 , 21, 608-614	10.3	143
48	The alternatively spliced murine pregnane X receptor isoform, mPXR(delta171-211) exhibits a repressive action. <i>International Journal of Biochemistry and Cell Biology</i> , 2010 , 42, 672-82	5.6	11
47	Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile?. <i>European Journal of Cancer</i> , 2010 , 46, 1800-7	7.5	33
46	Predictive markers for haematological toxicity of pemetrexed. <i>Current Drug Targets</i> , 2010 , 11, 48-57	3	9

45	Is it prime time for personalized medicine in cancer treatment?. <i>Personalized Medicine</i> , 2010 , 7, 387-397	2.2	1
44	Surface antigen profiling of colorectal cancer using antibody microarrays with fluorescence multiplexing. <i>Journal of Immunological Methods</i> , 2010 , 355, 40-51	2.5	26
43	Identification of distinctive protein expression patterns in colorectal adenoma. <i>Proteomics - Clinical Applications</i> , 2010 , 4, 60-70	3.1	32
42	Patient-doctor communication: use of complementary and alternative medicine by adult patients with cancer. <i>Society for Integrative Oncology</i> , 2010 , 8, 56-64		25
41	Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. <i>Oncology</i> , 2009 , 77, 113-9	3.6	94
40	Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials. <i>BMC Cancer</i> , 2009 , 9, 130	4.8	32
39	Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO. <i>BMC Cancer</i> , 2009 , 9, 153	4.8	21
38	Adjuvant chemotherapy for stage C colonic cancer in a multidisciplinary setting. <i>ANZ Journal of Surgery</i> , 2009 , 79, 685-92	1	4
37	Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2009 , 101, 998-1004	8.7	73
36	Cetuximab-associated pulmonary toxicity. <i>Clinical Colorectal Cancer</i> , 2009 , 8, 118-20	3.8	31
35	Ethnic differences in drug metabolism and toxicity from chemotherapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009 , 5, 243-57	5.5	89
34	Beyond Conventional Cancer Treatments: "The Use of Complementary Therapies During Cancer Treatment: Implications for Clinicians" 2009 , 285-315		
33	Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2008 , 7, 331-7	3.8	82
32	Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008 , 4, 137-49	5.5	64
31	Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2013-9	2.2	2328
30	Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. <i>Clinical Cancer Research</i> , 2008 , 14, 817-25	12.9	81
29	Medical Qigong for cancer patients: pilot study of impact on quality of life, side effects of treatment and inflammation. <i>The American Journal of Chinese Medicine</i> , 2008 , 36, 459-72	6	59
28	Patient and physician preferences for surgical and adjuvant treatment options for rectal cancer. <i>Archives of Surgery</i> , 2008 , 143, 389-94		69

27	Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2006-12	2.2	667
26	Retrospective review of mitomycin C use as third-line chemotherapy in metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008 , 4, 132-136	1.9	2
25	Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy. <i>Clinical Colorectal Cancer</i> , 2007 , 6, 578-82	3.8	2
24	The development of multiple reaction monitoring assays for liver-derived plasma proteins. <i>Proteomics - Clinical Applications</i> , 2007 , 1, 1570-81	3.1	34
23	Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. <i>Supportive Care in Cancer</i> , 2007 , 15, 301-7	3.9	96
22	Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4228-35	2.2	28
21	Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 7492-7	12.9	64
20	Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival. <i>Nutrition and Cancer</i> , 2006 , 55, 78-85	2.8	112
19	Predicting the toxicity of weekly docetaxel in advanced cancer. <i>Clinical Pharmacokinetics</i> , 2006 , 45, 611-22	2.2	27
18	Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count. <i>Clinical Colorectal Cancer</i> , 2006 , 6, 297-304	3.8	27
17	Advances in the adjuvant treatment of colorectal cancer. <i>ANZ Journal of Surgery</i> , 2006 , 76, 373-80	1	14
16	An evaluation of the prevalence of malnutrition in cancer patients attending the outpatient oncology clinic. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2006 , 2, 80-86	1.9	22
15	Changes in quality of life in patients with advanced cancer: evidence of response shift and response restriction. <i>Journal of Psychosomatic Research</i> , 2005 , 58, 497-504	4.1	49
14	A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2005 , 49, 401-12	5.9	22
13	Nutritional assessment in cancer: comparing the Mini-Nutritional Assessment (MNA) with the scored Patient-Generated Subjective Global Assessment (PGSGA). <i>Nutrition and Cancer</i> , 2005 , 53, 51-6	2.8	90
12	The relationship between available support, unmet needs and caregiver burden in patients with advanced cancer and their carers. <i>Psycho-Oncology</i> , 2005 , 14, 102-14	3.9	134
11	Factors affecting cytochrome P-450 3A activity in cancer patients. <i>Clinical Cancer Research</i> , 2004 , 10, 8341-50	12.9	107
10	Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. <i>British Journal of Clinical Pharmacology</i> , 2004 , 57, 44-53	3.8	54

9	Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. <i>Lancet Oncology, The</i> , 2003 , 4, 224-32	21.7	181
8	Baseline nutritional assessment in advanced cancer patients receiving palliative chemotherapy. <i>Nutrition and Cancer</i> , 2003 , 46, 148-57	2.8	68
7	The erythromycin breath test for the prediction of drug clearance. <i>Clinical Pharmacokinetics</i> , 2001 , 40, 151-8	6.2	52
6	Unusual presentations of germ cell tumors. Case 1. Recurrent laryngeal nerve palsy in mediastinal seminoma. <i>Journal of Clinical Oncology</i> , 2001 , 19, 909-11	2.2	2
5	Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance. <i>Cancer Chemotherapy and Pharmacology</i> , 2000 , 45, 9-14	3.5	11
4	Clinical and preclinical pharmacokinetics of raltitrexed. <i>Clinical Pharmacokinetics</i> , 2000 , 39, 429-43	6.2	19
3	Vinblastine pharmacokinetics in patients with non-small cell lung cancer given cisplatin. <i>Cancer Investigation</i> , 1999 , 17, 479-85	2.1	2
2	Clinical pharmacokinetics of docetaxel. <i>Clinical Pharmacokinetics</i> , 1999 , 36, 99-114	6.2	328
1	Clinical management and treatment outcomes of Merkel cell carcinoma. <i>ANZ Journal of Surgery</i> , 1998 , 68, 354-8	1	43